טוען...
Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein
Globally, human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in newborns, young children, and the elderly for which there is no vaccine. The RSV fusion (F) glycoprotein is a major target for vaccine development. Here, we describe a novel monoclonal antib...
שמור ב:
| הוצא לאור ב: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Public Library of Science
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6366758/ https://ncbi.nlm.nih.gov/pubmed/30730999 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0210749 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|